Key result
Atrial amyloidosis in AF ablation linked to ~2.7-fold higher risk of major cardiovascular events.
Why the study?
This study aimed to assess the prevalence of cardiac amyloidosis in non-valvular AF and test whether early-stage cardiac amyloidosis can be identified via atrial biopsy.
Does the presence of atrial amyloidosis increase the risk of adverse cardiovascular outcomes in patients undergoing atrial fibrillation ablation?
Cohort (n=578)
Yes
Does the presence of atrial amyloidosis increase the risk of adverse cardiovascular outcomes in patients undergoing atrial fibrillation ablation?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“atrial biopsy detected atrial amyloidosis in ~7% of patients, often at an early stage, highlighting its potential for earlier diagnosis and intervention”
Atrial biopsy safely identifies early-stage cardiac amyloidosis in 7% of AF ablation patients, revealing a subset with advanced atrial cardiomyopathy and significantly worse cardiovascular outcomes.
BACKGROUND AND AIMS: This study aimed to assess the prevalence of cardiac amyloidosis (CA) in patients with non-valvular atrial fibrillation (AF) and to test the hypothesis that early-stage CA can be identified through atrial biopsy. METHODS: Atrial biopsy was performed on 578 patients during AF ablation, with right ventricular (RV) biopsy conducted in 385 patients. The amyloid type was assessed using immunohistochemistry. Patients were classified into groups of atrial biopsy-detected CA (abio-CA) and non-CA, with an additional 58 patients clinically diagnosed with CA comprising the clinical CA group. RESULTS: Amyloid deposits were identified in atrial samples from 40 patients (7%), including 25 amyloid transthyretin (ATTR) types. Prevalence increased to 20%-40% with advancing age, left ventricular (LV) hypertrophy, and the presence of low-voltage areas in the left atrium. The abio-CA group exhibited a thinner LV posterior wall (11.3 ± 2.2 vs 15.3 ± 4.6 mm, P < .001) compared with the clinical CA group. The abio-CA group displayed a thicker LV posterior wall (11.3 ± 2.2 vs 9.6 ± 1.4 mm, P < .001) and a higher frequency of low-voltage areas defined as <0.5 mV (45% vs 13%, P < .001) compared with the non-CA group. Right ventricular biopsy identified amyloid deposits in 13 patients (3%), comprising 11 ATTR and 2 light-chain types. Among the 26 patients in the abio-CA group who underwent RV biopsy, 13 had no amyloid deposits in RV samples, indicating confined atrial amyloidosis. CONCLUSIONS: Atrial biopsy revealed amyloid deposits in 7% of patients undergoing AF ablation, identifying early-stage CA.
No takes yet. Share an insight, caveat, or question.
Shinzato et al. (2025) conducted a cohort in Non-valvular atrial fibrillation (n=578). Atrial amyloidosis (atrial biopsy-detected) vs. Absence of atrial amyloidosis (non-CA) was evaluated on Composite of all-cause mortality, stroke, and hospitalization for heart failure (adjusted hazard ratio 2.71, 95% CI 1.10-6.70). Atrial amyloidosis was found in 7% of AF ablation patients and independently increased the risk of death, stroke, and heart failure hospitalization.
Synapse has enriched 10 related papers. Consider them for comparative context: